title: Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
authors: Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
authors: Massimo
authors: M
authors: Breccia
authors: Laura
authors: L
authors: Cannella
authors: Mauro
authors: M
authors: Nanni
authors: Caterina
authors: C
authors: Stefanizzi
authors: Giuliana
authors: G
authors: Alimena
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D013844:Thiazoles; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib